section name header

Pronunciation

kan-a-bi-DYE-ol

Classifications

Therapeutic Classification: anticonvulsants

Pharmacologic Classification: cannabinoids

Indications

REMS

Action

Therapeutic Effects:

Pharmacokinetics

Absorption: Extent of absorption unknown. High-fat/high-calorie meals increase extent of absorption.

Distribution: Extensively distributed to tissues.

Protein Binding: >94%.

Metabolism/Excretion: Primarily metabolized in the liver by the CYP2C9 and CYP3A4 isoenzymes to an active metabolite (7-OH-CBD). Primarily excreted in feces.

Half-life: 56–61 hr.

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
POunknown2.5–5 hrunknown

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Derm: rash.

EENT: dry mouth.

GI: liver enzymes, diarrhea, abdominal pain, hepatotoxicity.

GU: serum creatinine.

Hemat: anemia.

Metab: appetite, weight.

Neuro: fatigue, insomnia, sedation, aggressive behavior, agitation, ataxia, SUICIDAL THOUGHTS/BEHAVIORS.
Misc: (INCLUDING ANGIOEDEMA)HYPERSENSITIVITY REACTIONS , infection, physical dependence, psychological dependence (high doses or prolonged therapy).

Interactions

Drug-Drug:

Route/Dosage

Seizures Associated with Lennox-Gastaut Syndrome or Dravet Syndrome

Hepatic Impairment

Seizures Associated with Tuberous Sclerosis Complex

Hepatic Impairment

Availability

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Epidiolex

Contr. Subst. Schedule

Schedule V (C-V)